Electrical substance clearance from the brain for treatment of Alzheimer's disease

Patent metadata

Field	Value
Publication number	US-9724515-B2
Application number	US-201514926705-A
Country	US
Kind code	B2
Filing date	Oct 29, 2015
Priority date	Oct 29, 2015
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

Apparatus is provided that includes a parenchymal electrode, configured to be implanted in brain parenchyma of a subject identified as at risk of or suffering from Alzheimer's disease; and a ventricular electrode, configured to be implanted in a ventricular system of a brain of the subject. Control circuitry is configured to drive the parenchymal and the ventricular electrodes to clear a substance from the brain parenchyma into the ventricular system. Other embodiments are also described.

First claim

The invention claimed is:

1. Apparatus comprising:
a parenchymal electrode, configured to be implanted in brain parenchyma of a subject identified as at risk of or suffering from Alzheimer's disease;
a ventricular electrode, configured to be implanted in a ventricular system of a brain of the subject; and
control circuitry, configured to drive the parenchymal and the ventricular electrodes to clear a substance from the brain parenchyma into the ventricular system by applying direct current between the parenchymal and the ventricular electrodes using an average voltage of less than 1.2 V, the substance comprising one or more substances selected from the group of substances consisting of: amyloid beta, tau protein, and metal ions.

2. The apparatus according to claim 1 , wherein the substance includes amyloid beta, and wherein the control circuitry is configured to drive the parenchymal and the ventricular electrodes to clear the amyloid beta from the brain parenchyma into the ventricular system.

3. The apparatus according to claim 1 , wherein the substance includes tau protein, and wherein the control circuitry is configured to drive the parenchymal and the ventricular electrodes to clear the tau protein from the brain parenchyma into the ventricular system.

4. The apparatus according to claim 1 , wherein the control circuitry is configured to drive the parenchymal and the ventricular electrodes to clear the substance by applying the direct current as non-excitatory current between the parenchymal and the ventricular electrodes.

5. The apparatus according to claim 1 , wherein the control circuitry is configured to apply the direct current as a series of pulses.

6. The apparatus according to claim 5 , wherein the control circuitry is configured to apply the direct current as the series of pulses having an average pulse duration of between 100 milliseconds and 300 seconds.

7. The apparatus according to claim 5 , wherein the control unit is configured to:
measure a current resulting from application of voltage during each of the pulses, and
terminate the pulse upon the measured current falling below a threshold value.

8. A method comprising:
implanting a parenchymal electrode in brain parenchyma of a subject identified as at risk of or suffering from Alzheimer's disease;
implanting a ventricular electrode in a ventricular system of a brain of the subject; and
activating control circuitry to drive the parenchymal and the ventricular electrodes to clear a substance from the brain parenchyma into the ventricular system by applying direct current between the parenchymal and the ventricular electrodes using an average voltage of less than 1.2 V, the substance comprising one or more substances selected from the group of substances consisting of: amyloid beta, tau protein, and metal ions.

9. The method according to claim 8 , wherein the substance includes amyloid beta, and wherein activating the control circuitry comprises activating the control circuitry to drive the parenchymal and the ventricular electrodes to clear the amyloid beta from the brain parenchyma into the ventricular system.

10. The method according to claim 8 , wherein the substance includes tau protein, and wherein activating the control circuitry comprises activating the control circuitry to drive the parenchymal and the ventricular electrodes to clear the tau protein from the brain parenchyma into the ventricular system.

11. The method according to claim 8 , wherein activating the control circuitry to drive the parenchymal and the ventricular electrodes comprises activating the control circuitry to drive the parenchymal and the ventricular electrodes to clear the substance by applying the direct current as non-excitatory current between the parenchymal and the ventricular electrodes.

12. The method according to claim 8 , wherein activating the control circuitry to apply the direct current comprises activating the control circuitry to apply the direct current as a series of pulses.

13. The method according to claim 12 , wherein activating the control circuitry to apply the direct current as the series of pulses comprises activating the control circuitry to apply the direct current as the series of pulses having an average pulse duration of between 100 milliseconds and 300 seconds.

14. The method according to claim 12 , wherein activating the control circuitry to drive the parenchymal and the ventricular electrodes comprises activating the control unit to:
measure a current resulting from application of voltage during each of the pulses, and
terminate the pulse upon the measured current falling below a threshold value.

15. The method according to claim 8 , wherein implanting the parenchymal and the ventricular electrodes comprises implanting the parenchymal and the ventricular electrodes such that an area of build-up of the substance is between the parenchymal and the ventricular electrodes.

16. The method according to claim 8 , wherein implanting the parenchymal electrode comprises implanting the parenchymal electrode such that an area of build-up of the substance is between the parenchymal electrode and an area of the ventricular system nearest the area of build-up.

Assignees

• Rainbow Medical Ltd

Inventors

• Fostick Gideon
• Gross Yossi

Classifications

• A61N1/327

  for enhancing the absorption properties of tissue, e.g. by electroporation · CPC title

• A61N1/0534

  Electrodes for deep brain stimulation · CPC title

• A61N1/0529 Primary

  Electrodes for brain stimulation · CPC title

• A61N1/306

  Arrangements where at least part of the apparatus is introduced into the body · CPC title

• A61N1/36082 Primary

  Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease · CPC title